Literature DB >> 1692080

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

M A Caligiuri1, A Zmuidzinas, T J Manley, H Levine, K A Smith, J Ritz.   

Abstract

In this study, we have used radiolabeled IL-2 binding assays, Northern blot analysis, immunofluorescent flow cytometry and cell sorting, as well as proliferation and cytotoxicity assays to perform an extensive phenotypic and functional characterization of the IL-2 receptor in normal resting human peripheral blood lymphocytes. Our results indicate that almost all T cells (greater than 98%) express neither the high affinity IL-2 receptor nor the functional intermediate affinity p75 chain of the IL-2 receptor without prior activation. In contrast, most NK cells constitutively express the isolated intermediate affinity p75 IL-2 receptor. In addition, a subpopulation of NK cells, distinguished by high density expression of the NKH1 antigen, constitutively express the high affinity IL-2 receptor, in addition to an excess of the isolated intermediate affinity p75 IL-2 receptor. These NKH1bright+ cells exhibit a brisk proliferative response to IL-2, similar to that seen with antigen-activated T cells, yet do so in the absence of any known antigenic stimuli. No other resting peripheral blood lymphocyte population, including CD4+, CD8+, and CD20 cells, exhibits this property. The intermediate affinity p75 IL-2 receptor, as it exists in its isolated form on resting NK cells, does not transduce a growth signal equivalent to that seen in NK cells expressing the high affinity IL-2 receptor, despite doses of IL-2 that are known to fully saturate the isolated p75 chain. This strongly suggests that additional structural or functional components are involved in generating the proliferative response following the binding of IL-2 to the high affinity heterodimeric form of the IL-2 receptor. The constitutive expression of this functional high affinity IL-2 receptor on a small population of resting NK cells provides further evidence in support of a role for these cells in the host's early defense against viral infection or malignant transformation, before the more delayed but specific T cell response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692080      PMCID: PMC2187895          DOI: 10.1084/jem.171.5.1509

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  48 in total

1.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

Authors:  J H Kehrl; M Dukovich; G Whalen; P Katz; A S Fauci; W C Greene
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

2.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.

Authors:  L L Lanier; A M Le; C I Civin; M R Loken; J H Phillips
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

Review 4.  Human T lymphocyte subsets. Functional heterogeneity and surface recognition structures.

Authors:  P L Romain; S F Schlossman
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

5.  Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein.

Authors:  L T Bich-Thuy; M Dukovich; N J Peffer; A S Fauci; J H Kehrl; W C Greene
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

6.  Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.

Authors:  A Harel-Bellan; J Bertoglio; A Quillet; C Marchiol; H Wakasugi; Z Mishall; D Fradelizi
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

7.  Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes.

Authors:  L T Bich-Thuy; H C Lane; A S Fauci
Journal:  Cell Immunol       Date:  1986-04-01       Impact factor: 4.868

8.  Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.

Authors:  J E Talmadge; R H Wiltrout; D F Counts; R B Herberman; T McDonald; J R Ortaldo
Journal:  Cell Immunol       Date:  1986-10-15       Impact factor: 4.868

9.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.

Authors:  J J Mulé; J Yang; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

10.  Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo.

Authors:  J F Bukowski; J F Warner; G Dennert; R M Welsh
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  99 in total

1.  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Authors:  T A Fehniger; E M Bluman; M M Porter; E Mrózek; M A Cooper; J B VanDeusen; S R Frankel; W Stock; M A Caligiuri
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Suchitra Pandey; Vanessa A York; Janice Arakawa-Hoyt; Hanspeter Pircher; Philip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

Review 3.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

4.  Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells.

Authors:  Philip J Norris; Dale F Hirschkorn; Deborah A DeVita; Tzong-Hae Lee; Edward L Murphy
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

5.  Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Authors:  Sawa Ito; Catherine M Bollard; Mattias Carlsten; Jan Joseph Melenhorst; Angélique Biancotto; Ena Wang; Jinguo Chen; Yuri Kotliarov; Foo Cheung; Zhi Xie; Francesco Marincola; Kazushi Tanimoto; Minoo Battiwalla; Matthew J Olnes; Shira Perl; Paula Schum; Thomas E Hughes; Keyvan Keyvanfar; Nancy Hensel; Pawel Muranski; Neal S Young; A John Barrett
Journal:  Mol Ther       Date:  2014-04-01       Impact factor: 11.454

6.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

7.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

8.  Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7.

Authors:  G Monteleone; T Parrello; F Luzza; F Pallone
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

9.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Authors:  J W Gratama; R J Bruin; C H Lamers; R Oosterom; E Braakman; G Stoter; R L Bolhuis
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  Supplementation with selenium augments the functions of natural killer and lymphokine-activated killer cells.

Authors:  L Kiremidjian-Schumacher; M Roy; H I Wishe; M W Cohen; G Stotzky
Journal:  Biol Trace Elem Res       Date:  1996-06       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.